Seqalis is proud to contribute its quantitative analytical expertise to the Oncode Accelerator Therapeutic Vaccines Workstream. Through its patented qTCR-Seq technology and collaborative approach, Seqalis helps strengthen the development of next-generation therapeutic cancer vaccines with robust, data-driven insights. Read the full article to learn how this collaboration is supporting innovation in cancer immunotherapy.

On Jan. 25 2023, Seqalis broadcasted a live expert panel on immuno-oncology and quantitative TCR sequencing. The webinar was organized by Seqalis with the collaboration of the Institut de Duve (UCLouvain, Be) and PDC-Line Pharma (Be/Fr). The expert panel was composed of Dr Sophie Lucas, President of de Duve Institute (UCLouvain, Be), Eric Halioua, CEO of PDC-Line Pharma (Fr/Be), Dr Joël Plumas, CSO of PDC-Line Pharma (Be/Fr) and Dr Javier Carrasco, clinical oncologist at the Grand Hôpital de Charleroi (Be) and Medical Advisor of Seqalis. The webinar turned out to be an overwhelming...